Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A ...
A concise, high-yield guide to cholesterol-lowering therapies—statins, Zetia, PCSK9 inhibitors, bempedoic acid, berberine, and key dietary tweaks—plus insights on benefits, risks, and mechanisms.
WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lipid-lowering drugs, were associated with a 22% lower risk for nonmelanoma skin cancer (NMSC) in patients with atherosclerotic ...
Low back pain is a leading global cause of disability, and the musculoskeletal impact of lipid-lowering drugs (e.g., statins, PCSK9 inhibitors) used for coronary heart disease (CHD) prevention has ...
Adding a PCSK9 inhibitor to maximally tolerated statins after a coronary or peripheral artery revascularization can help patients achieve LDL cholesterol goals better than standard care, data from the ...
Strong preclinical evidence suggested PCSK9 inhibitors may overcome immunotherapy resistance by preventing tumor cells from evading the immune system. In patients with lung cancer, melanoma, or kidney ...
Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used. PCSK9 inhibitors represent one of the ...
A pooled analysis of three randomized controlled trials shows the oral PCSK9 inhibitor enlicitide reduces LDL cholesterol by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results